Amezinium metilsulfate, a sympathomimetic agent, may increase the risk of urinary retention in multiple system atrophy.
In 5 patients with multiple system atrophy, administration of 15 mg/day of amezinium metilsulfate, an adrenergic agent, during 6 months for the treatment of postural hypotension exacerbated post-micturition residuals as compared to that before treatment (178 ml versus 113 ml for a change of 37 %, p < 0.05). Amezinium metilsulfate most probably stimulates both alpha1B-receptors in the vascular wall and alpha1A/D-receptors in the proximal urethra.
Sakakibara
Ryuji
R
Department of Neurology, Chiba University, 1-8-1 Inohana Chuo-ku, Chiba 260-8670, Japan. sakaki@med.m.chiba-u.ac.jp
Uchiyama
Tomoyuki
T
Asahina
Masato
M
Yoshiyama
Mitsuharu
M
Yamanishi
Tomonori
T
Hattori
Takamichi
T
D000368:Aged; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D019578:Multiple System Atrophy / Q000150:complications*; D011724:Pyridazines / Q000009:adverse effects* / Q000627:therapeutic use; D012189:Retrospective Studies; D013566:Sympathomimetics / Q000009:adverse effects* / Q000627:therapeutic use; D016055:Urinary Retention / Q000139:chemically induced*; D014563:Urodynamics / Q000187:drug effects / Q000502:physiology
D011724:Pyridazines; D013566:Sympathomimetics; C027784:amezinium